Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCX 434
- Development stage
- Preclinical
- Lead developer
- NicOx
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Ophthalmic, Intravitreal
01
Overview
NCX 434 is a novel nitric oxide (NO)-donating derivative of triamcinolone acetonide, developed for ophthalmic use. It is designed to combine the anti-inflammatory effects of glucocorticoids with the vasodilatory and oxygenation-enhancing properties of NO donation. Preclinical studies have shown that NCX 434 enhances optic nerve head (ONH) oxygen saturation, reduces oxidative stress markers, and attenuates inflammatory cytokines more effectively than standard triamcinolone acetonide. Unlike conventional steroids, it does not significantly increase intraocular pressure (IOP), addressing a key safety concern in steroid-based ocular therapies. The drug has demonstrated efficacy in preclinical models of ischemia/reperfusion injury and diabetic macular edema (DME), suggesting potential for treating retinal diseases characterized by hypoxia and inflammation[1][3][4][5][6].
- Other names
- nitric oxide-donating triamcinolone acetonide
02
Targets
GR (Glucocorticoid receptor)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on NCX 434.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCX 434.